👉NTRB is TODAY’S #1 ALERT 👈

Hey folks, Jeff Bishop here.

I’ve been on a roll this week with my “tactical trade” ideas.

Three of them hit double-digit intraday gains, and a fourth one reached *only* 7%.

My signature move this week has been identifying stocks that had great recent runups before retracing back to support levels.

Today’s “tactical trade” idea has followed that same pattern…

I last alerted this one back at the beginning of June. That day, it soared an impressive 31% intraday.

The stock actually had a 45% single-day move at the start of July, so it’s no stranger to big days.

💥Go ahead and pull up Nutriban Inc. (NTRB) on your favorite trading platform.

If you take a look at its chart, you’ll see it has done very well this year. It’s up 51% YTD, outpacing the S&P 500’s performance more than six-fold.

And since its April 7 low, NTRB has recovered 58%, nearly doubling the S&P 500’s 31% recovery.

As I suggested, the stock is now sitting at a support level, and it spent almost all of June and July above this point, so I’m looking for a bounce.

I’m expecting big things for NTRB today, and I suggest keeping a close eye on it.

👉  NTRB is TODAY’S #1 ALERT 👈

Here are my top five things that stand out about this innovative company:

1. AVERSA™: The Game-Changer in Opioid Safety 💊🔒

Nutriband’s biggest innovation, AVERSA, is a patch technology designed for transdermal drug delivery, especially for abuse-prone drugs like opioids. The tech incorporates “aversive agents” to deter abuse of potent drugs like fentanyl. AVERSA is patented in 46 countries, including major markets such as the US, Europe, Japan, and China.

2. Strategic Partnership with Kindeva Drug Delivery 🤝🚀

In February, Nutriband inked an exclusive development partnership with Kindeva Drug Delivery to develop its lead product, AVERSA Fentanyl, potentially the world’s first abuse-deterrent fentanyl patch. The idea is to incorporate AVERSA’s abuse-deterrent tech into Kindeva’s FDA-approved transdermal fentanyl patch. 

This collaboration involves shared development costs and milestone payments from Kindeva, which CEO Gareth Sheridan says has “allowed us to reduce the impact of dilution to our existing shareholders.” He adds that not diluting shareholders “has been and will remain a core focus of the company.”

3. Projected Market Impact 📈💰

If approved by the FDA, AVERSA Fentanyl is projected to achieve peak annual U.S. sales of $80 million – $200 million. The product is pursuing a streamlined 505(b)(2) NDA regulatory pathway, which requires only a single Phase 1 trial and has the potential for an expedited six-month FDA review. 

Its next candidate, AVERSA Buprenorphine, is projected to reach peak annual sales of $70M – $130M, if approved.

4. Expanding Brand Visibility through Sports Partnerships ⚽📣

To enhance brand recognition, Nutriband has signed an Associate Partnership agreement with Charlotte Football Club, a Major League Soccer team based in North Carolina. The goal is to increase visibility for Nutriband’s AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.

5. Recent Financial Performance 📊💼

On June 2, Nutriband reported its fiscal 2025 Q1 earnings revenues of $0.67 million for the quarter — up 63% year-over-year — and set a revenue target of $0.71 million for the next quarter.

Final Thoughts

NTRB stands out as a pre-profit pharma that actually has revenue thanks to its manufacturing arm, Pocono Pharma. That helps keep the lights on while it chases the big AVERSA payday.

The stock received a reiterated BUY rating from Noble Financial on June 20 with a $15.00 12-month price target — 116% upside from yesterday’s closing price.

As you do your own research, have a look at the company website, this investor webinar from October 2024, and the company’s X page.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: NTRB has dramatically outpaced the S&P 500 this year — with its 51% YTD gain and its 58% recovery from its April low. 

It soared 31% the day I alerted it in June, and it’s now sitting at a support level.

💥Dial into NTRB to see if we get a bounce from here!

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, received twenty five hundred dollars (cash) from Primetime Media for advertising Nutriband Inc for a one day marketing program on August 8, 2025. Prior to this, we received forty thousand dollars (cash) from TD Media for advertising Nutriband Inc for a one day marketing program on June 2, 2025. It might seem obvious, but while our client claims not to own any shares in XYZ Corp, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into XYZ Corp might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.